OHR Pharmaceutical Inc. (OHRP) and Quanterix Corporation (NASDAQ:QTRX) Comparing side by side

Both OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Quanterix Corporation (NASDAQ:QTRX) are each other’s competitor in the Biotechnology industry. Thus the compare of their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OHR Pharmaceutical Inc. N/A 0.00 13.24M -0.22 0.00
Quanterix Corporation 33.34M 14.42 30.40M -2.07 0.00

In table 1 we can see OHR Pharmaceutical Inc. and Quanterix Corporation’s gross revenue, earnings per share (EPS) and valuation.


Table 2 has OHR Pharmaceutical Inc. and Quanterix Corporation’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
OHR Pharmaceutical Inc. 0.00% -62.7% -54.6%
Quanterix Corporation -91.18% -53.8% -37.5%


OHR Pharmaceutical Inc. has a Current Ratio of 5.5 and a Quick Ratio of 5.5. Competitively, Quanterix Corporation’s Current Ratio is 4.1 and has 3.8 Quick Ratio. OHR Pharmaceutical Inc.’s better ability to pay short and long-term obligations than Quanterix Corporation.

Insider and Institutional Ownership

OHR Pharmaceutical Inc. and Quanterix Corporation has shares held by institutional investors as follows: 14.6% and 68.6%. 8.91% are OHR Pharmaceutical Inc.’s share held by insiders. Comparatively, insiders own roughly 11.9% of Quanterix Corporation’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
OHR Pharmaceutical Inc. -5.33% -32.38% -25.58% -34.41% -90.21% -92.37%
Quanterix Corporation 6.51% 14.84% 28.61% 18.88% 14.25% -7.03%

For the past year OHR Pharmaceutical Inc. was more bearish than Quanterix Corporation.


Quanterix Corporation beats OHR Pharmaceutical Inc. on 5 of the 9 factors.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and SR-X system that supports the detection capability of approximately six biomarkers per test. The company's products also comprise kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, assay development, and custom development services. Quanterix Corporation primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.